Fig. 5

TIGAR knockdown sensitized HL-60 leukemia cells to glycolysis inhibition in vivo. a Western blotting analysis of HL-60 xenograft tumor samples. The ascites-derived tumor cells from mice were collected and lysed at the end of the study, and western blotting analyses of TIGAR and TUBULIN were performed (n = 2 for each group). b The survival of HL-60 xenograft mice with the combined treatment of TIGAR knockdown and 2-DG. 1 × 10⁶ HL-60 cells with or without TIGAR knockdown were inoculated into BALB/c (nu/nu) nude mice (n = 10). Those mice were treated or untreated with 2-DG (2 g/kg, PO, QD) from 1-week post implantation of HL-60 cells. c In HL-60 xenograft tumor mice, the effectiveness of TIGAR knockdown in combination with 2-DG in treating HL-60 xenograft tumor mice correlated with decreased percentages of HL-60 leukemia cells in PB. FACS analysis showed the decrease of HL-60 cells in PB of HL-60 xenograft tumor mice. Mean ± SD was shown. d Photomicrographs of hematoxylin and eosin-stained spleen sections from HL-60 xenograft tumor mice with the combined treatment of TIGAR knockdown and 2-DG. e The combined treatment of TIGAR knockdown and 2-DG induced apoptosis of HL-60 leukemia cells in mice. The HL-60 cells from ascites fluid were collected and stained with PI and Annexin-V, and the percentages of PI⁻/Annexin-V⁺, representing apoptotic cells, were determined by FACS (n = 5). Mean ± SD was shown